Search Results - "Pistamaltzian, N"

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence by Brown, Tommy A., Mittendorf, Elizabeth A., Hale, Diane F., Myers, John W., Peace, Kaitlin M., Jackson, Doreen O., Greene, Julia M., Vreeland, Timothy J., Clifton, G. Travis, Ardavanis, Alexandros, Litton, Jennifer K., Shumway, Nathan M., Symanowski, J., Murray, James L., Ponniah, Sathibalan, Anastasopoulou, E. A., Pistamaltzian, N. F., Baxevanis, Constantin N., Perez, Sonia A., Papamichail, Michael, Peoples, George E.

“…Purpose AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen…”
Get full text

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence by Mittendorf, E.A., Ardavanis, A., Symanowski, J., Murray, J.L., Shumway, N.M., Litton, J.K., Hale, D.F., Perez, S.A., Anastasopoulou, E.A., Pistamaltzian, N.F., Ponniah, S., Baxevanis, C.N., von Hofe, E., Papamichail, M., Peoples, G.E.

“…AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776–790). Phase I studies showed AE37 administered with granulocyte macrophage…”
Get full text

1077 Ovarian Malignant Ascites-derived Lymphocytes Stimulated With Prothymosin Alpha or Its Immunoactive Decapeptide Lyse Autologous Tumor Cells in Vitro and Retard Tumor Growth in SCID Mice by Voutsas, I.F, Pistamaltzian, N, Tsiatas, M.L, Skopeliti, M, Katsila, T, Dimopoulos, M.A, Bamias, A, Tsitsilonis, O.E

Get full text

1457 POSTER The Clinical Significance of CRP and Serum Albumin in Primary Lung Cancers by Tsoukalas, N, Oikonomaki, T, Tolia, M, Tzovaras, A, Papakostidi, A, Pistamaltzian, N, Ardavanis, A, Barbounis, V, Theocharis, S, Liaskonis, K

Get full text

1075 POSTER The Clinical Significance of RCAS1 Expression in Primary Lung Neoplasms by Tsoukalas, N, Oikonomaki, T, Papakostidi, A, Pistamaltzian, N, Tsiambas, E, Karameris, A, Ardavanis, A, Manolis, E, Theocharis, S, Kittas, C

Get full text

Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer by Tsoukalas, N, Tzovaras, A A, Tolia, M, Kostakis, I D, Papakostidi, A, Pistamaltzian, N, Ardavanis, A

“…The monoclonal antibody cetuximab that targets epidermal growth factor receptor (EGFR) has been found effective in the treatment of colorectal cancer. However,…”
Get more information

W04.146 Correlation between IL-1$beta;, IL-6 and HDL serum levels by PISTAMALTZIAN, N

Get full text

Preexisting immunity as a potential biomarker for clinical response to AE37 vaccination in breast cancer patients by Pistamaltzian, N.F., Anastasopoulou, E.A., Tzonis, P., Kalogeropoulou, J., Ardavanis, A., Mittendorf, E.A., Peoples, G.E., Baxevanis, C.N., Papamichail, M., Perez, S.A.

Get full text

Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice by Voutsas, Ioannis F, Pistamaltzian, Nikolaos, Tsiatas, Marinos L, Skopeliti, Margarita, Katsila, Theodora, Mavrothalassiti, Ilektra, Spyrou, Spyros, Dimopoulos, Meletios-Athanassios, Tsitsilonis, Ourania E, Bamias, Aristotelis

“…Abstract Background Tumour-associated lymphocytes (TALs) present in effusions of ovarian cancer patients exhibit impaired activities, due to the…”
Get full text

P1-13-01: An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence by Hale, DF, Perez, S, Sears, AK, Clifton, GT, Vreeland, TJ, Holmes, JP, Ardavanis, A, Pistamaltzian, N, Rellias, G, Ponniah, S, Papamichail, M, Peoples, GE, Mittendorf, EA

“…Abstract Introduction AE37 is the Ii-Key hybrid of the HER2−derived peptide AE36 (HER2:776–790). A phase I trial administering AE37 with the immunoadjuvant…”
Get full text

P4-11-15: Increased Propability of Triple Negative Breast Cancer (TNBC) in Premenopausal Patients after Exogenous Hormonal Intake (EHI) by Pistamaltzian, NF, Tzavara, C, Papadimitriou, C, Gyftaki, R, Tryfonopoulos, D, Panopoulos, C, Tsoukalas, N, Koumakis, G, Demiri, S, Koufopoulos, N, Misitzis, Y, Apostolikas, N, Efremidis, A

“…Abstract Purpose: HRT is a known risk factor for breast cancer (BC) among post-menopausal women. Our knowledge in relation to EHI (estrogens and/or progestin)…”
Get full text

Abstract P6-10-06: Metachronous Contralateral Breast Cancer (CBC) Has More Aggressive Biology and Clinical Characteristics Compared to Synchronous Bilateral Breast Cancer (BBC) by Pistamaltzian, NF, Papadimitriou, C, Panopoulos, C, Koumakis, G, Demiri, S, Tsoukalas, N, Yannoukakos, D, Apostolikas, N, Panagopoulos, E, Efremidis, A.

“…Abstract Purpose: Bilateral breast cancer is an uncommon clinical entity. There is no specific treatment strategy and controversial issues concerning…”
Get full text

W04.146 Correlation between IL-1β, IL-6 and HDL serum levels by Pistamaltzian, N., Regli, A., Drosos, T., Caroni, C., Kosioni, E., Ligoura, P., Zografos, P., Konstantinidis, I.

Get full text